TFPI-2 methylation predicts poor prognosis in non-small cell lung cancer

Lung Cancer

Volumn 76, Issue 1, 2012, Pages 106-111

  Wu, Duoguang ^a   Xiong, Lihua ^a   Wu, Shuoming ^a   Jiang, Ming ^a   Lian, Guiyong ^a   Wang, Minghui ^a  

^a SUN YAT SEN MEMORIAL HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

Author keywords

Methylation; Multivariate analyses; Non small cell lung cancer; Prognosis; Survival; TFPI 2

Indexed keywords

DNA; PLACENTA PROTEIN 5;

ADENOSQUAMOUS CARCINOMA; ADULT; AGE; AGED; ARTICLE; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; CIGARETTE SMOKING; COMORBIDITY; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DISEASE SEVERITY; DNA METHYLATION; FEMALE; GROUPS BY AGE; HUMAN; HUMAN TISSUE; LARGE CELL CARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEX DIFFERENCE; SURVIVAL RATE; SURVIVAL TIME;

ADENOCARCINOMA; CARCINOMA, LARGE CELL; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; DNA METHYLATION; DNA, NEOPLASM; FEMALE; FOLLOW-UP STUDIES; GLYCOPROTEINS; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; REAL-TIME POLYMERASE CHAIN REACTION; RNA, NEOPLASM; SURVIVAL RATE;

EID: 84858006527     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2011.09.005     Document Type: Article

References (24)

1. Parkin D.M., Bray F., Ferlay J., Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005, 55:74-108.
2. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Thun M.J. Cancer statistics, 2009. CA Cancer J Clin 2009, 59:225-249.
3. Jin F., Devesa S.S., Chow W.H., Zheng W., Ji B.T., Fraumeni J.F., et al. Cancer incidence trends in urban shanghai, 1972-1994: an update. Int J Cancer 1999, 83:435-440.
4. Etzioni R., Urban N., Ramsey S., McIntosh M., Schwartz S., Reid B., et al. The case for early detection. Nat Rev Cancer 2003, 3:243-252.
5. Zochbauer-Muller S., Gazdar A.F., Minna J.D. Molecular pathogenesis of lung cancer. Annu Rev Physiol 2002, 64:681-708.
6. Minna J.D., Fong K., Zochbauer-Muller S., Gazdar A.F. Molecular pathogenesis of lung cancer and potential translational applications. Cancer J 2002, 8 Suppl 1:S41-S46.
7. Burstein H.J., Schwartz R.S. Molecular origins of cancer. N Engl J Med 2008, 358:527.
8. Issa J.P. CpG island methylator phenotype in cancer. Nat Rev Cancer 2004, 4:988-993.
9. Anglim P.P., Alonzo T.A. Laird-Offringa IA. DNA methylation-based biomarkers for early detection of non-small cell lung cancer: an update. Mol Cancer 2008, 7:81.
10. Wong C.M., Ng Y.L., Lee J.M., Wong C.C., Cheung O.F., Chan C.Y., et al. Tissue factor pathway inhibitor-2 as a frequently silenced tumor suppressor gene in hepatocellular carcinoma. Hepatology 2007, 45:1129-1138.
11. Glöckner S.C., Dhir M., Yi J.M., McGarvey K.E., Van Neste L., Louwagie J., et al. Methylation of TFPI2 in stool DNA: a potential novel biomarker for the detection of colorectal cancer. Cancer Res 2009, 69:4691-4699.
12. Sato N., Parker A.R., Fukushima N., Miyagi Y., Iacobuzio-Donahue C.A., Eshleman J.R., et al. Epigenetic inactivation of TFPI-2 as a common mechanism associated with growth and invasion of pancreatic ductal adenocarcinoma. Oncogene 2005, 24:850-858.
13. Nobeyama Y., Okochi-Takada E., Furuta J., Miyagi Y., Kikuchi K., Yamamoto A., et al. Silencing of tissue factor pathway inhibitor-2 gene in malignant melanomas. Int J Cancer 2007, 121:301-307.
14. Sova P., Feng Q., Geiss G., Wood T., Strauss R., Rudolf V., et al. Discovery of novel methylation biomarkers in cervical carcinoma by global demethylation and microarray analysis. Cancer Epidemiol Biomarkers Prev 2006, 15:114-123.
15. Rollin J., Iochmann S., Bléchet C., Hubé F., Régina S., Guyétant S., et al. Expression and methylation status of tissue factor pathway inhibitor-2 gene in non-small-cell lung cancer. Br J Cancer 2005, 92:775-783.
16. Wang S., Xiao X., Zhou X., Huang T., Du C., Yu N., et al. TFPI-2 is a putative tumor suppressor gene frequently inactivated by promoter hypermethylation in nasopharyngeal carcinoma. BMC Cancer 2010, 10:617.
17. Takada H., Wakabayashi N., Dohi O., Yasui K., Sakakura C., Mitsufuji S., et al. Tissue factor pathway inhibitor 2 (TFPI2) is frequently silenced by aberrant promoter hypermethylation in gastric cancer. Cancer Genet Cytogenet 2010, 197:16-24.
18. Lakka S.S., Konduri S.D., Mohanam S., Nicolson G.L., Rao J.S. In vitro modulation of human lung cancer cell line invasiveness by antisense cDNA of tissue factor pathway inhibitor-2. Clin Exp Metastasis 2000, 18:239-244.
19. Herman J.G., Graff J.R., Myöhänen S., Nelkin B.D., Baylin S.B. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 1996, 93:9821-9826.
20. Chen W.D., Han Z.J., Skoletsky J., Olson J., Sah J., Myeroff L., et al. Detection in fecal DNA of colon cancer-specific methylation of the nonexpressed vimentin gene. J Natl Cancer Inst 2005, 97:1124-1132.
21. Ma S., Chan Y.P., Kwan P.S., Lee T.K., Yan M., Tang K.H., et al. MicroRNA-616 induces androgen-independent growth of prostate cancer cells by suppressing expression of tissue factor pathway inhibitor TFPI-2. Cancer Res 2011, 71:583-592.
22. Konduri S.D., Tasiou A., Chandrasekar N., Nicolson G.L., Rao J.S. Role of tissue factor pathway inhibitor-2 (TFPI-2) in amelanotic melanoma (C-32) invasion. Clin Exp Metastasis 2000, 18:303-308.
23. Cox G., Steward W.P., O'Byrne K.J. The plasmin cascade and matrix metalloproteinases in non-small cell lung cancer. Thorax 1999, 54:169-179.
24. Chintala S.K., Tonn J.C., Rao J.S. Matrix metalloproteinases and their biological function in human gliomas. Int J Dev Neurosci 1999, 17:495-502.